Investor Relations

AMS at a Glance

Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced woundcare markets.

Our primary focus is to create quality outcomes for our:

  • Customers
  • Patients
  • Shareholders

Financial Calendar

Full Year Period End

31 December 2021

Half Year Period End

30 June 2021

Final Dividend Payment

18 June 2021

Annual General Meeting

June 2021

Preliminary Results Announcement

17 March 2021
View Full Calendar

Financial Reports

Notice of AGM

April 2021

2020 Interim Report

September 2020

Notice of AGM

May 2020

2019 Interim Report

September 2019

2018 Interim Report

September 2018

2017 Interim Report

September 2017

2016 Interim Report

September 2016

2015 Interim Report

October 2015

2014 Interim Report

September 2014
View All Reports

News

Acquisition of Raleigh Coatings

Advanced Medical Solutions Group plc today announces that it has acquired Raleigh Adhesive Coatings Limited (“Raleigh”), an independent woundcare and bio-diagnostics... Read More

Acquisition of Biomatlante

Advanced Medical Solutions Group plc today announces it has acquired French company Biomatlante SA (“Biomatlante”), a well-established international developer and manufacturer... Read More

View More News

Latest Highlights

Having created a designated COVID-19 working group, prioritised safe working practices and complied with government measures on social distancing, all AMS sites have remained in operation throughout the pandemic and the Group has been able to service the demand of its healthcare partners throughout 2020 while maintaining its robust balance sheet.

COVID-19 restrictions disrupted our global markets in 2020, with a resulting slowdown in surgical and wound treatment volumes. In addition, reduced access to hospitals has significantly restricted business development activities during the year. In line with consensus market forecasts, Group sales and profitability were heavily impacted. Group revenue declined to £86.8 million (2019: £102.4 million) and the resulting adverse operating leverage led to adjusted profit before tax reducing to £13.4 million (2019: £26.6 million) and adjusted diluted earnings per share reducing to 5.4p (2019: 9.8p).

Investment in R&D increased to £7.9 million (2019: £6.5 million) as progress continued on all key projects across the Group. We received approval and launched LiquiBand® Rapid™ and successfully completed LiquiBand® XL clinical trials, which keeps us on track for approval and launch towards the end of 2021. Progress on the US clinical trial for LiquiBandFix8® progressed well with a filing expected in 2022. Patient enrolment for the first human clinical study of Seal-G® and Seal-G® MIST began in February and CE mark extensions for the product are expected imminently giving AMS access to a new $1 billion addressable market with a differentiated product to fulfil a significant unmet need.

The acquisition of Raleigh Adhesive Coatings Limited in November 2020 for £22 million provides a strong strategic fit with commercial synergies and new commercial opportunities.

Given the Group’s strong net cash position and reflecting the Board’s confidence in the future, an increased full year dividend is proposed. In line with best practice, AMS repaid the £0.4 million of UK Government furlough support received during the year.

As COVID-19 vaccine programmes roll out in key markets, we await the reduction in infection rates and a gradual return to normalised levels of elective surgery across all of our markets.